Literature DB >> 1429101

Preliminary results in heavy charged particle irradiation of bone sarcoma.

V Uhl1, J R Castro, K Knopf, T L Phillips, J M Collier, P L Petti, I Daftari.   

Abstract

Between 1979 and 1989, 17 patients with unfavorable bone sarcoma were treated wholly or in part with heavy charged particle irradiation (helium and/or neon ions) at the University of California Lawrence Berkeley Laboratory. The majority of tumors were located near critical structures such as the spinal cord or brain. Gross tumor was present in all but two patients at the time of irradiation. Six patients were treated for recurrent disease. Histologies included osteosarcoma, Ewing's sarcoma, and recurrent osteoblastoma. Four of the osteosarcomata were believed to have been induced by previous therapeutic irradiation for various tumors. Follow-up time since initiation of radiation ranged from 7 to 118 months (median 40 months). The 5-year Kaplan-Maier local control rate was 48%; the corresponding survival rate was 41%. Over half the patients succumbed to distant metastases despite the majority of patients receiving chemotherapy. In this preliminary study, we have shown that heavy charged particle irradiation can be effectively used for control of bone sarcoma. A Phase II trial is warranted to determine optimal treatment for unresectable or gross residual disease.

Entities:  

Mesh:

Year:  1992        PMID: 1429101     DOI: 10.1016/0360-3016(92)90725-w

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

Review 1.  Results of heavy ion radiotherapy.

Authors:  J R Castro
Journal:  Radiat Environ Biophys       Date:  1995-03       Impact factor: 1.925

2.  Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility.

Authors:  Eleanor A Blakely; Bruce Faddegon; Christopher Tinkle; Charles Bloch; Michael Dominello; Robert J Griffin; Michael C Joiner; Jay Burmeister
Journal:  J Appl Clin Med Phys       Date:  2019-10-01       Impact factor: 2.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.